Prof. Dr. Turgay Çelikel
OncologyVerified
- 47+years exp.
English · Turkish
FromPrice on request
Free quote
60 seconds · no obligationView Profile
Cancer Surgery
Topical therapy of melanoma
What topical therapy of melanoma involves, how immune-modulating creams such as imiquimod work on the skin, and when dermatologists consider topical treatment for lentigo maligna or skin metastases instead of surgery. Covers clinical evidence, approximate treatment costs across Turkey, the UK, US and Germany, application protocols, expected skin reactions, risks, and how to verify an oncology centre.
A written plan with the surgeon's name and the full price — usually within 24 hours.
- Category
- Cancer Surgery
- Hospitals
- 2
- Verified
- 1
- Price from
- Price on request
Verified surgeons for Topical Therapy of Melanoma
1 doctor Compare doctors, ratings and prices — ask any of them for a free quote.
Topical therapy of melanoma: what it is and how it works
Topical therapy of melanoma describes the application of medicinal creams to treat cancerous or pre-cancerous cells in the surface layers of the skin. In modern oncology, standard primary treatment for melanoma is complete surgical removal with wide margins. However, topical treatments—most notably imiquimod 5% cream—occupy a recognised clinical role. They are primarily used for lentigo maligna, a form of melanoma in situ that develops on chronically sun-damaged skin in older adults, where surgery could cause severe cosmetic or functional damage. They are also occasionally used for superficial cutaneous metastases. Hospitals in Turkey offer dermato-oncology assessments to evaluate whether non-surgical therapy is appropriate.
Topical therapy cannot treat invasive melanoma that has spread into the deeper dermis or lymph nodes. This guide explains how topical agents work, what clinical evidence confirms, approximate costs compared with the UK, US and Germany, candidate criteria and recovery. For wider cancer care options, see our guide to oncology treatments in Turkey.
How do topical agents work against melanoma cells?
The main medication used is imiquimod, an immune response modifier rather than a direct chemotherapy. When applied to the skin, imiquimod binds to toll-like receptor 7 (TLR-7) on local immune cells. This triggers the release of pro-inflammatory cytokines, including interferon-alpha and tumour necrosis factor-alpha. These chemical signals summon cytotoxic T-cells and natural killer cells directly to the lesion, directing the body's immune defences to destroy abnormal melanocytes.
Other agents, such as topical retinoids or 5-fluorouracil, are occasionally studied in combination protocols to enhance absorption, but imiquimod monotherapy remains the recognised off-label standard when surgery cannot proceed. The treatment depends on creating an active local inflammatory response; without redness and inflammation, immune clearance does not take place.
Does topical therapy of melanoma actually work?
Clinical evidence for topical imiquimod for melanoma is encouraging for early surface disease but strictly limited by depth. For lentigo maligna (melanoma in situ), clinical trials report complete visible clearance in approximately 70 to 80 per cent of patients following a standard 12-to-16-week course. Histological clearance confirmed by post-treatment biopsy averages 70 to 75 per cent. While helpful for patients unfit for surgery, this is noticeably lower than the 95 per cent or higher cure rate achieved with surgical excision or Mohs surgery.
A key limitation is that atypical melanocytes often extend down hair follicles, where creams do not penetrate deeply. Consequently, recurrence rates reach 15 to 25 per cent over five years. For invasive melanoma, evidence shows creams are ineffective. Trustworthy oncologists never recommend topical treatment when invasive disease is suspected.
Topical therapy of melanoma cost in Turkey compared with the UK, US and Germany
The figures below provide approximate cost ranges for complete diagnostic evaluation, medication and clinical monitoring, rather than hospital-specific quotes. Total topical therapy of melanoma cost depends on diagnostic imaging, pathology fees, medication duration and the frequency of specialist reviews.
| Country | Approximate cost range |
|---|---|
| Turkey | €1,200 – €3,500 |
| United Kingdom | €2,800 – €7,500 |
| United States | €4,000 – €11,000 |
| Germany | €2,500 – €6,800 |
When evaluating the topical therapy of melanoma price, check what a clinic package includes. In Turkey, packages usually cover consultations, dermoscopy, biopsy pathology review, prescribed medications and coordination. Always confirm whether follow-up tele-consultations or post-treatment biopsies incur extra fees.
Topical therapy versus surgical excision and radiotherapy
Choosing between topical creams and surgical excision involves weighing clearance rates against cosmetic impact. Surgery remains the definitive standard, but non-surgical choices are considered when margins would damage eyelids, lips or the nose. In oncology, tissue-sparing approaches are carefully balanced against margin control, comparable to the principles used in a lumpectomy for breast tumours.
| Treatment method | Best suited to | Typical limits |
|---|---|---|
| Topical therapy (Imiquimod) | Lentigo maligna in elderly or surgically frail patients; delicate facial areas | Lower cure rate; no surgical margin verification; prolonged visible inflammation |
| Wide surgical excision | Invasive melanoma and standard primary choice for melanoma in situ | Leaves scars; may require skin flaps or grafts in facial zones |
| Mohs micrographic surgery | Facial melanoma in situ where maximum tissue conservation is needed | Requires specialised surgical team; higher procedural cost |
| Superficial radiotherapy | Large lentigo maligna in patients unable to tolerate surgery or creams | Risk of late radiation tissue changes; limited treatment access |
A multidisciplinary dermato-oncology team evaluates lesion size, location and patient health before deciding which approach offers the safest balance.
Who is a candidate for topical therapy of melanoma?
A good candidate for topical treatment for lentigo maligna is an adult diagnosed with biopsy-proven melanoma in situ who cannot undergo surgery due to medical frailty, advanced age, or severe heart conditions, or who faces major facial disfigurement from wide surgical margins. It is also considered when surgical margins remain positive after prior resections and further surgery is not possible.
Poor candidates include anyone with invasive melanoma (Breslow thickness greater than zero), nodular lesions, or pigmentation extending deep into follicles. It is also unsuitable for patients who cannot tolerate severe local inflammation, those with active autoimmune disorders, pregnant women, and anyone unable to attend strict follow-up appointments.
Treatment protocol step by step: application and clinical monitoring
Undergoing topical therapy of melanoma in Turkey follows a structured, step-by-step clinical protocol:
- Diagnostic biopsy and mapping: A biopsy confirms the lesion is in situ with no invasive cells. High-resolution dermoscopy records baseline borders.
- Application schedule: Imiquimod cream is applied four to five nights per week at bedtime, spreading a thin film over the lesion and a 5 to 10 millimetre margin of normal skin.
- Application method: The skin is cleansed, dried, and the cream is left on for six to eight hours before washing off.
- Treatment duration: The course runs for 12 to 16 weeks, guided by the patient's inflammatory response.
- Clinical monitoring: Regular reviews ensure the inflammation is strong enough to clear melanocytes without causing deep ulceration.
- Post-treatment assessment: Eight to twelve weeks after finishing, repeat biopsies or confocal microscopy confirm clearance.
Unlike surgical procedures such as the removal of colon cancer where resected margins are confirmed immediately by pathology, topical therapy yields no specimen, making long-term monitoring essential.
Before and after topical treatment: what realistic results look like
Before-and-after photographs show a distinct pattern that surprises many patients. During the first two months, the skin looks considerably worse than before treatment. The area becomes bright red, swollen, weeping, and covered with heavy scabs as the immune system attacks abnormal melanocytes.
Once healed, usually two to three months after stopping the cream, realistic results show clear or substantially lightened skin. Some mild hypopigmentation (pale patches) or faint redness may remain. Before-and-after photos do not guarantee that microscopic cells in deep follicles are completely gone. Honest clinics show unedited photos of both the peak inflamed stage and the final healed skin.
Recovery, skin reactions and managing treatment side effects
The topical therapy of melanoma recovery timeline revolves around active inflammation rather than wound healing from a single surgical cut:
- Weeks 1–2: Mild redness and minor itching begin as the immune system responds. Daily routines continue normally.
- Weeks 3–8: Peak inflammation. The skin becomes intensely red, crusted, and sore. Mild flu-like fatigue or low fever may occur and can be eased with paracetamol.
- Weeks 9–16: Sustained inflammation. The specialist may adjust application frequency to manage discomfort.
- Weeks 17–24: Treatment ceases. Crusting clears and new skin forms within two to four weeks. Strict sun protection is essential.
- Months 6 onwards: Skin tone settles. Ongoing specialist checks continue every three to six months.
Patients travelling to Turkey usually stay four to seven nights for initial biopsy review and training, continuing treatment at home with remote clinical support.
Risks, limitations and clinical safety
The primary oncological risk is under-treating hidden invasive melanoma. If an initial biopsy misses an invasive focus, using cream alone allows cancer cells to invade deeper tissue and spread. Guidance from the National Health Service (NHS), the British Association of Dermatologists (BAD), and the American Academy of Dermatology (AAD) stresses that topical creams are not a replacement for surgery in standard melanoma cases.
Local side effects include pain, heavy crusting, skin erosion, and risk of secondary bacterial infection. Permanent skin lightening or darkening can also occur. Systemic side effects include mild flu-like symptoms. Any spreading infection or severe pain must be reported to the medical team promptly.
How to choose an oncology centre and questions to ask
When researching topical therapy of melanoma Turkey, select a licensed hospital with an experienced dermato-oncology multidisciplinary tumour board. The clinic should have advanced dermoscopy and access to surgical oncologists if excision becomes necessary. Facilities offering broad oncology treatments in Turkey ensure comprehensive care if the lesion fails to clear.
Red flags include clinics that prescribe creams without a biopsy, promise guaranteed cures, or offer no follow-up plan. Review how our process works and request an assessment through our free quote page before travelling. Essential questions to ask include:
- Has a biopsy confirmed the lesion is purely in situ with no invasive cells?
- What specific weekly application schedule do you recommend for my lesion?
- How will you verify whether the lesion has completely cleared after treatment?
- What is your protocol if the skin reaction becomes too painful or infected?
- What surgical alternatives are available if topical therapy fails?
- What schedule of follow-up checks will I need over the next five years?
Conditions treated with Topical Therapy of Melanoma
Hospitals with Oncology in Turkey
Frequently asked questions
Topical therapy of melanoma refers to applying medicated creams, primarily imiquimod 5%, directly to the skin to stimulate a local immune response. It is used almost exclusively for lentigo maligna (melanoma in situ) when surgical excision is unfeasible, or occasionally for superficial skin metastases under specialist oncological supervision.
It can be effective for superficial melanoma in situ (lentigo maligna), with studies showing clinical clearance in roughly 70 to 80 per cent of selected patients. However, it does not penetrate deep skin layers and is not suitable for invasive melanoma, where surgical removal remains the essential standard of care.
Complete evaluation and supervised topical treatment packages in Turkey typically range from €1,200 to €3,500. This includes comprehensive dermatological mapping, baseline dermoscopy or confocal microscopy, specialist oncology consultations, the prescribed medication course, and follow-up clinical assessments. Costs in the UK and US are generally substantially higher.
During treatment, the treated skin looks significantly worse before it improves, becoming red, crusted, and inflamed as the immune system attacks abnormal cells. Once healed, the original pigmented lesion often fades or disappears completely, though post-inflammatory hypopigmentation or faint redness can persist for several months.
The active treatment phase typically lasts 12 to 16 weeks, followed by 4 to 8 weeks for the acute skin inflammation, redness, and crusting to heal. Full tissue recovery and cosmetic stabilisation may take up to six months, after which careful long-term dermatological surveillance is required.
The cream itself does not sting immediately on application, but as the immune response activates over two to three weeks, the skin becomes tender, itchy, and sore. Some patients also experience mild flu-like symptoms, including fatigue and low-grade aching, which can be managed with paracetamol and soothing emollients.
Successful clearance can provide long-lasting remission, but recurrence rates are higher than with standard surgical excision, reaching 15 to 25 per cent over five years in lentigo maligna. Because dormant atypical melanocytes can persist along hair follicles, regular long-term follow-up examinations are vital.
When prescribed and monitored by a qualified dermato-oncologist, topical therapy is safe. The primary safety risk is not the medication itself, but misdiagnosing an invasive melanoma as in situ, allowing cancer cells to spread deeper untreated. A prior histological biopsy is mandatory before starting therapy.
Surgical wide local excision is the gold-standard treatment, offering cure rates exceeding 95 per cent with clear histological margin verification. Topical therapy is reserved for cases where surgery would cause severe facial disfigurement or where medical frailties make surgery hazardous, accepting a slightly higher risk of recurrence.
Patients travelling to Turkey usually stay 4 to 7 days for initial dermatological mapping, biopsy confirmation, staging review, and treatment initiation. The daily cream application is then carried out at home with structured remote tele-oncology reviews, followed by a planned return visit for formal clearance assessment.
Patient stories